Independent association of elevated serum hepatocyte growth factor levels with development of insulin resistance in a 10-year prospective study

Summary Objective Hepatocyte growth factor (HGF) receptors form a hybrid complex with insulin receptors in the liver of mice, which lead to robust signalling to regulate glucose metabolism. Serum HGF levels are high in subjects with metabolic syndrome and/or obesity. Accordingly, we prospectively in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical endocrinology (Oxford) 2013-07, Vol.79 (1), p.43-48
Hauptverfasser: Tsukagawa, Eri, Adachi, Hisashi, Hirai, Yuji, Enomoto, Mika, Fukami, Ako, Ogata, Kinuka, Kasahara, Akiko, Yokoi, Kanako, Imaizumi, Tsutomu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Objective Hepatocyte growth factor (HGF) receptors form a hybrid complex with insulin receptors in the liver of mice, which lead to robust signalling to regulate glucose metabolism. Serum HGF levels are high in subjects with metabolic syndrome and/or obesity. Accordingly, we prospectively investigated the relationship between HGF and the development of insulin resistance (IR) in a general population without IR at baseline. Methods A total of 1492 subjects received health examinations. After excluding subjects with diabetes and/or IR (n = 402) at baseline, the remaining subjects (n = 1090) were followed‐up 10 years later. Complete data sets were available from 716 subjects for prospective analysis. Logistic regression was performed to determine factors associated with the development of IR after 10 years. Results In subjects without diabetes at baseline, serum HGF levels were higher (0·26 ± 0·10 ng/ml, n = 259) in subjects with IR than without it (0·22 ± 0·09 ng/ml, n = 1090). After deleting subjects who developed liver disease during follow‐up, 188 were found to have developed IR at 10 years after the original screening. HGF (P 
ISSN:0300-0664
1365-2265
DOI:10.1111/j.1365-2265.2012.04496.x